| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f48ce965f3bef3a9407622abd0b87bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adc2242e8bdf393deaf02d4f7c71d326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bfa8e9cc5b06751d30556acefc410fed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b0233a12a758360018d73129f09645b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21ea9a1737ec651354b6cd75aaaba0b9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2002-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8332371f38c5f6e90eaa7f00cdb61ae8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf607dfc56023a5543c67e5f110b7fb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ee5c54428b14bd467a6e38ee14a05ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd4c0f72a0ac6de2b61beca7aeb50d8f |
| publicationDate |
2005-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03044040-A9 |
| titleOfInvention |
Alpha-fetoprotein peptides and uses thereof |
| abstract |
Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-stimulated growth of cells, and treating or preventing cancer, such as breast cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy. |
| priorityDate |
2001-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |